{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:15:16Z","timestamp":1790252116601,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T00:00:00Z","timestamp":1187308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In AIDS\/Kaposi's sarcoma (KS) patients, the sensitivity of immunofluorescence assays for detecting antibodies against latent nuclear antigen ranges from 52% to 93%. However, in classic and African KS, sensitivities above 90% have been reported systematically. This study evaluates whether CD4+ T\u2010cell count affects seroreactivity to KSHV LANA and to lytic antigens in AIDS\/KS patients. Kaposi's sarcoma\u2010associated herpesvirus (KSHV) latent (IFA\u2010LANA) and lytic (IFA\u2010Lytic and ORF65\/K8.1 EIA) antibodies were screened in 184 consecutive samples taken from 36 AIDS\/KS patients grouped according to their CD4+ counts as follows: &lt;100 (group A), 100\u2013300 (group B), and &gt;300 (group C) cells\/mm\n                    <jats:sup>3<\/jats:sup>\n                    . At enrollment, the immunofluorescence assay for the detection of antibodies against latent nuclear antigen (IFA\u2010LANA) was positive in 3\/11(27.2%) group A patients, in 10\/11 (90.9%) group B patients, and in 14\/14 (100%) group C patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01). Seropositivity to lytic antigens did not differ according to CD4+ T\u2010cell count. Considering IFA\u2010Lytic and ORF65\/K8.1 EIA, seropositivity for lytic antigens was 100% in all three patient groups. In patients whose CD4+ count improved during follow\u2010up, IFA\u2010LANA seroconversion occurred; unstable counts resulted in a decrease in LANA antibody titers while the persistence of high counts resulted in unchanged, elevated antibody titers. In conclusion, LANA seroreactivity in AIDS\/KS patients, as assessed by an immunofluorescence assay, depends on CD4+ T\u2010cell count, rendering this evaluation important in the interpretation of seroepidemiological studies of KSHV infection in AIDS patients. To evaluate future serological tests based on latency\u2010associated antigens, the selection of sera from KS patients with CD4+ cell count &gt;300 cells\/mm\n                    <jats:sup>3<\/jats:sup>\n                    as a positive gold standard is recommended. J. Med. Virol. 79:1562\u20131568, 2007. \u00a9 Wiley\u2010Liss, Inc.\n                  <\/jats:p>","DOI":"10.1002\/jmv.20949","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T12:17:07Z","timestamp":1187353027000},"page":"1562-1568","source":"Crossref","is-referenced-by-count":11,"title":["Seroreactivity to Kaposi's sarcoma\u2010associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS\u2010associated Kaposi's sarcoma patients depends on CD4+ T\u2010cell count"],"prefix":"10.1002","volume":"79","author":[{"given":"Vanda Akico Ueda Fick","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia Camera","family":"Pierrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Masami","family":"Sumita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilton Santos","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aluisio Augusto Cotrim","family":"Segurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udio S\u00e9rgio","family":"Pannuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/345866"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2000.0778"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199912010-00003"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.4.1150-1153.1999"},{"key":"e_1_2_1_6_1","first-page":"44","article-title":"Acquired immunodeficiency syndrome\u2010related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome","volume":"28","author":"Cattelan AM","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1998.9055"},{"key":"e_1_2_1_8_1","first-page":"73","article-title":"Histopathological features of Kaposi's sarcoma in HIV infected individuals","volume":"10","author":"Cockerell CJ","year":"1991","journal-title":"Cancer Surv"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.5.913-921.2001"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.6.700"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200012)62:4<498::AID-JMV15>3.0.CO;2-B"},{"key":"e_1_2_1_12_1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00042560-200004010-00011","article-title":"Identifying human herpesvirus 8 infection: Performance characteristics of serologic assays","volume":"23","author":"Engels EA","year":"2000","journal-title":"J Acquir Immune Defic Synd"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70149-V"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0896-925"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.9.4838"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00272.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1128\/CDLI.7.3.427-435.2000","article-title":"New immunofluorescence assays for detection of human Herpesvirus \u2010specific antibodies","volume":"7","author":"Inoue N","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.8.3478-3485.2000"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0896-918"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2001000700007"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910360109"},{"key":"e_1_2_1_22_1","first-page":"531","article-title":"Kaposi's sarcoma: A new staging classification","volume":"67","author":"Krigel RL","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03240-0"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381403"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.2.696-701.2000"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10548"},{"key":"e_1_2_1_27_1","unstructured":"Minist\u00e9rio da Sa\u00fade.2007.Recomenda\u00e7\u00f5es para terapia anti\u2010retroviral em adolescentes e adultos infectados pelo HIV. Available athttp:\/\/www.aids.gov.br. Accessed 29 January 2007."},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01264-06"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00490.x"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1031"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/515649"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0396-342"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81919-0"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<361::AID-IJC9>3.0.CO;2-M"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07560-5"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2004000100017"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.6.2174-2180.2000"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013383"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1999.9674"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.20949","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.20949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T07:57:55Z","timestamp":1700035075000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.20949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,17]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1002\/jmv.20949"],"URL":"https:\/\/doi.org\/10.1002\/jmv.20949","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1091864.545185","asserted-by":"object"}]},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,17]]}}}